Scholarlink

<p>We appreciate the comments from Arshad et al. regarding our study on long-term outcomes of alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) in Japan. Addressing concerns about sex-related differences, our analyses revealed no significant differences between men and women in overall mortality (log-rank <i>P</i> = 0.759) or major cardiovascular events (heart failure admission, <i>P</i> = 0.521; pacemaker/implantable cardioverter-defibrillator implantation, <i>P</i> = 0.234; sustained ventricular tachycardia/ventricular fibrillation, <i>P</i> = 0.615; new-onset atrial fibrillation, <i>P</i> = 0.894). The 12% reintervention rate is consistent with reported rates from high-volume centers over 10&#xa0;years (10–15%), suggesting appropriate patient selection. Primary risk factors for reintervention were thicker interventricular septum and residual mitral regurgitation, as previously reported. Sustained efficacy of ASA is supported by 75% of patients maintaining NYHA class I at 10-year follow-up. These findings, while acknowledging potential differences between Japanese and Western populations, reinforce the long-term safety and effectiveness of ASA for HOCM in Japan.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reply to letter to the editor: “Long-term clinical outcomes after alcohol septal ablation for hypertrophic obstructive cardiomyopathy in Japan: a retrospective study”

  • 期刊论文

  • 发表日期：

    2025年2月4日

查看全文
  • Junya Matsuda,
  • Hitoshi Takano,
  • Yoichi Imori,
  • Kakeru Ishihara,
  • Hideto Sangen,
  • Yoshiaki Kubota,
  • Jun Nakata,
  • Hideki Miyachi,
  • Yusuke Hosokawa,
  • Shuhei Tara,
  • Yukichi Tokita,
  • Takeshi Yamamoto,
  • Mitsunobu Kitamura,
  • Morimasa Takayama,
  • Kuniya Asai

摘要

We appreciate the comments from Arshad et al. regarding our study on long-term outcomes of alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) in Japan. Addressing concerns about sex-related differences, our analyses revealed no significant differences between men and women in overall mortality (log-rank P = 0.759) or major cardiovascular events (heart failure admission, P = 0.521; pacemaker/implantable cardioverter-defibrillator implantation, P = 0.234; sustained ventricular tachycardia/ventricular fibrillation, P = 0.615; new-onset atrial fibrillation, P = 0.894). The 12% reintervention rate is consistent with reported rates from high-volume centers over 10 years (10–15%), suggesting appropriate patient selection. Primary risk factors for reintervention were thicker interventricular septum and residual mitral regurgitation, as previously reported. Sustained efficacy of ASA is supported by 75% of patients maintaining NYHA class I at 10-year follow-up. These findings, while acknowledging potential differences between Japanese and Western populations, reinforce the long-term safety and effectiveness of ASA for HOCM in Japan.